News November 17 2017

ReWalk Robotics announces pricing of follow-on public offering of ordinary shares

ReWalk Robotics Ltd. (Nasdaq: RWLK) (“ReWalk” or the “Company”) today announced that it has priced its underwritten public offering of 6,857,000 ordinary shares at a price to the public of $1.05 per ordinary share. All of the ordinary shares in the offering are to be sold by ReWalk. National Securities Corporation, a wholly-owned subsidiary of National Holdings Corporation (NASDAQ: NHLD), is acting as sole book-running manager of the offering. ReWalk has granted the underwriter a 45-day option to purchase up to 1,028,550 ordinary shares sold in the public offering on the same terms and conditions. The offering is expected to close on November 21, 2017, subject to customary closing conditions. ReWalk intends to use the net proceeds from the offering for (i) sales, marketing and reimbursement expenses related to market development activities and broadening third-party payor coverage and (ii) research and development costs related to developing its lightweight “soft suit” exoskeleton technology for various lower limb disabilities, including stroke and other indications affecting the ability to walk. The offering is being made under an effective registration statement on file with the Securities and Exchange Commission (the “SEC”). Copies of the preliminary prospectus may be obtained from National Securities Corporation, Attention: Marguerite Rogers, 200 Vesey Street, 25th Floor, New York, NY 10281, by telephone at (212) 417-8227, or by email at prospectusrequest@nationalsecurities.com. The preliminary prospectus is also available on the SEC’s website at www.sec.gov. The final terms of the offering will be disclosed in a final prospectus to be filed with the SEC and made available on the SEC’s website at www.sec.gov. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of the securities discussed in this press release in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. About ReWalk Robotics Ltd. ReWalk Robotics Ltd. develops, manufactures and markets wearable robotic exoskeletons for individuals with spinal cord injury. Our mission is to fundamentally change the quality of life for individuals with lower limb disability through the creation and development of market leading robotic technologies. Founded in 2001, ReWalk has headquarters in the U.S., Israel and Germany. ReWalk® is a registered trademark of ReWalk Robotics Ltd. in Israel. Forward-Looking Statements In addition to historical information, this press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, Section 27A of the U.S. Securities Act of 1933, and Section 21E of the U.S. Securities Exchange Act of 1934. Such forward-looking statements may include projections regarding ReWalk’s future performance and, in some cases, may be identified by words like “anticipate,” “assume,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “future,” “will,” “should,” “would,” “seek” and similar terms or phrases. The forward-looking statements contained in this press release are based on management’s current expectations, which are subject to uncertainty, risks and changes in circumstances that are difficult to predict and many of which are outside of ReWalk’s control. Important factors that could cause ReWalk’s actual results to differ materially from those indicated in the forward-looking statements include, among others: ReWalk’s expectations regarding future growth, including its ability to increase sales in its existing geographic markets, expand to new markets and achieve its planned expense reductions; the conclusion of ReWalk’s management for the financial statements for the third quarter of 2017 and for fiscal 2016, and the opinion of ReWalk’s auditors in their report on the Company’s financial statements for fiscal 2016, that there are substantial doubts as to ReWalk’s ability to continue as a going concern; ReWalk’s ability to maintain and grow its reputation and the market acceptance of its products; ReWalk’s ability to achieve reimbursement from third-party payors for its products; ReWalk’s expectations as to its clinical research program and clinical results; ReWalk’s expectations as to the results of, and the Food and Drug Administration’s potential regulatory developments with respect to, ReWalk’s mandatory post-market 522 surveillance study; the outcome of ongoing shareholder class action litigation relating to ReWalk’s initial public offering;  ReWalk’s ability to repay its secured indebtedness; ReWalk’s ability to improve its products and develop new products; ReWalk’s ability to maintain adequate protection of its intellectual property and to avoid violation of the intellectual property rights of others; ReWalk’s ability to gain and maintain regulatory approvals; ReWalk’s ability to secure capital from its equity and debt financings in light of limitations under its Form S-3, the price range of its ordinary shares and conditions in the financial markets, and the risk that such financings may dilute ReWalk’s shareholders or restrict its business; ReWalk’s ability to use effectively the proceeds of offerings of securities; ReWalk’s ability to maintain relationships with existing customers and develop relationships with new customers; the impact of the market price of ReWalk’s ordinary shares on the determination of whether ReWalk is a passive foreign investment company; ReWalk’s ability to comply with the continued listing requirements of the NASDAQ Capital Market and the risk that its ordinary shares will be delisted if it cannot do so; ReWalk’s compliance with medical device reporting regulations to report adverse events involving its products and the potential impact of such adverse events on ReWalk’s ability to market and sell its products; and other factors discussed under the heading “Risk Factors” in ReWalk’s Annual Report on Form 10-K for the year ended December 31, 2016, as amended, filed with the U.S. Securities and Exchange Commission and other documents subsequently filed with or furnished to the U.S. Securities and Exchange Commission. Any forward-looking statement made in this press release speaks only as of the date hereof. Factors or events that could cause ReWalk’s actual results to differ from the statements contained herein may emerge from time to time, and it is not possible for ReWalk to predict all of them. Except as required by law, ReWalk undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise.

News November 2 2017

MariaDB completes Series C funding led by Alibaba Group, finishing 2017 with $54m in global investment

MariaDB® Corporation, the company behind the fastest growing open source database, today announced that it raised $27 million in an investment led by Alibaba Group, with participation from existing investors Intel Capital, California Technology Ventures, Tesi, SmartFin Capital and Open Ocean. Combined with a recent $27 million investment from the European Investment Bank(EIB), this latest capital brings MariaDB’s total funding this year to $54 million. MariaDB will continue its collaboration with Alibaba Cloud, the cloud computing arm of Alibaba Group, to deliver new solutions for the cloud and emerging use cases. MariaDB reaches more than 60 million developers worldwide through its inclusion in every major Linux distribution, as well as a growing presence in the world’s major cloud providers. The latest investments reflect the rising interest in MariaDB from every commercial region around the world. “Companies around the world are standardizing on open source for modern application development,” said Michael Howard, CEO of MariaDB Corporation. “From global banks to leading telecommunication companies, MariaDB is selected over proprietary offerings for its complete set of database features built for the next generation of applications. This investment allows MariaDB to further accelerate growth, while delivering new solutions for the cloud and automation through machine learning.” MariaDB’s open source model and active community participation enable the company to iterate more quickly and add new industry-leading capabilities faster than closed, proprietary software vendors like Oracle. Technology giants Alibaba, Facebook, Tencent and others have collaborated with MariaDB to develop and incorporate significant features, including multi-source replication, encryption, point-in-time rollback and more that address new and emerging challenges and opportunities. Alibaba Cloud is a valued MariaDB contributor and user. MariaDB and Alibaba Cloud companies have worked closely together to enhance features of products such as AliSQL, a cloud-friendly open source project that enables Alibaba’s work with MariaDB. “MariaDB is becoming the gold standard for enterprise-grade open source databases,” said Jin Li, Vice President of Alibaba Cloud. “We believe that the symbiotic relationships found in the open source community contribute to the success of both MariaDB’s database technology and our cloud platform, and we have an opportunity to build some truly innovative solutions for cloud, on premise and hybrid deployments.” MariaDB Empowers Mobility in the Cloud With the widespread adoption of cloud architectures, comes increasing concern that cloud vendor lock-in brings the same lack of choice as proprietary systems. In contrast, MariaDB is deployment agnostic, free from cloud vendor lock-in and engineered to handle transactional, analytical, and web-scale workloads across any public, private or hybrid topology. MariaDB’s mobility affords customers unparalleled flexibility and power with a best-of-breed, open source database. Record MariaDB Business Growth Today’s global investment news comes on the heels of a momentous 2017 fiscal year, which ended September 30, with record business growth. Rapid Revenue Expansion: MariaDB ended the fiscal year and last quarter with historical revenue gains. The average deal size doubled as customers deployed MariaDB across growing segments of their business, including the first enterprise-wide replacement and migration from Oracle Enterprise to MariaDB. New Database Solution Offerings: In 2017, MariaDB continued its track record of innovative development through the availability of two new database solution offerings: MariaDB TX, a complete database solution for transactional workloads, and MariaDB AX, a modern data warehousing solution for high-performance analytics. Debuted Inaugural MariaDB User Conference: In April, MariaDB hosted its first-ever annual user conference to address the fast-growing business usage of MariaDB. With participation from hundreds of customers, partners and developers from around the world, the conference reflected MariaDB’s growing global presence in the enterprise. As a general purpose database, MariaDB has been deployed to support a wide range of applications in every industry, from credit card transactions and investment applications in banking, to customer phone data and billing applications in telecom, to inventory, purchases and order fulfillment applications in e-commerce. With the ability to fulfill any transactional or analytical workload, MariaDB supports the most critical applications at companies around the world. Its widespread use across Linux distributions and cloud platforms, as well as its ease of use, have quickly made MariaDB the open source database standard for the modern enterprise.

News September 7 2017

TiGenix has obtained a licence for commercial production at its Spanish facility

TiGenix has obtained a licence for the commercial production of expanded adipose-derived stem cells (eASCs) at its expanded manufacturing facility in Madrid, Spain, following an inspection by the Spanish Medicines Agency (AEMPS). This licence will provide the company with production capacity for the potential European commercial roll out of Cx601, which is an investigational stem cell therapy for the treatment of complex perianal fistulas in patients with Crohn’s disease. Additionally, this expanded facility offers the company the opportunity to manufacture other pipeline products. “We are very pleased with this approval for our expanded facility, which confirms our state-of-the-art GMP manufacturing capabilities in the stem cell field,” said Wilfried Dalemans, Chief Technical Officer at TiGenix. “We have now significantly increased our manufacturing capacity, a key step in the preparation for commercialization of Cx601 in Europe and in the further development of our pipeline.” The company has submitted a marketing authorisation (MA) application for Cx601 to the European Medicines Agency (EMA) and a decision is anticipated this year. Should it be approved it will enable marketing of the product in all 28 EU member states as well as Norway, Iceland and Lichenstein. Cx601 has been licensed to Takeda for exclusive development and commercialization outside of the US.